Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient

Abstract

Arterial hypertension is one of the major causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reduction in blood pressure is essential to reduce individual cardiovascular risk. In daily clinical practice, single-pill fixed-dose combinations of different drug classes are important therapeutic resources that could improve both treatment adherence and cardiovascular risk management by targeting distinct pathophysiological mechanisms. The aim of this practical narrative review is to help physicians choosing the right single-pill fixed-dose combination for the right patient in the daily clinical practice, based on the individual clinical phenotype and cardiovascular risk profile.

Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities

“…Overweight or obese patients who are also affected by arterial hypertension usually need antihypertensive combination strategies to obtain proper 24-h coverage ( 90 , 166 ). First-choice drugs are ARBs or ACE-I, preferably used at the highest dosages ( 167 ).…”

An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention

“…Indeed, the association of Rosuvastatin-Amlodipine, addressing two major cardiovascular RFs simultaneously in a simple and effective way, meets the requirements implied by a more thorough cardiovascular prevention. Moreover, this combination provided in the single-pill formulation appears to be more effective in reducing both BP and lipid values than the two separate agents [ 51 , 52 ]. Kim and colleagues showed that subjects who received the association Rosuvastatin-Amlodipine achieved the greatest reduction in systolic and diastolic BP levels and in LDL-c levels compared to those who were treated with only Rosuvastatin or Amlodipine.…”

Chronotherapy of hypertension: current state of the problem and prospects

“…Антигипертензивная эффективность, положительное влияние на метаболические показатели и хорошая переносимость тройной фиксированной комбинации амлодипина/ индапамида/периндоприла аргинина продемонстрирована в ряде зарубежных и российских исследований [64][65][66][67][68][69][70][71]. Хронофармакологических исследований Трипликсама не проводилось, однако опубликованный дополнительный анализ исследования ТРИКОЛОР (54 участника программы с валидными парными результатами СМАД), показавший равномерный антигипертензивный эффект препарата в течение суток [72], и некоторые зарубежные работы [73][74][75] позволяют предположить, что Трипликсам будет одинаково эффективен при приеме и в утренние, и в вечерние часы.…”